Abstracts tagged "COVID-19"

Abstract Number: 0896 • ACR Convergence 2021
Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination
Medha Barbhaiya¹, Jonah Levine¹, Caroline Siegel¹, Vivian Bykerk², Deanna Jannat-Khah¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Vaccination against SARS-CoV-2 is particularly important for patients with systemic lupus erythematosus (SLE), who may be at increased risk of hospitalization for COVID-19. However,…
Abstract Number: 1086 • ACR Convergence 2021
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA
Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
Abstract Number: 1533 • ACR Convergence 2021
Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
Claudia Marques¹, Ana Paula Reis², Adriana Kakehasi³, Edgard Neto⁴, Marcelo Medeiros Pinheiro⁵, Gecilmara Salviato Pileggi⁶, Gilda Ferreira⁷, Licia Maria Henrique Mota⁸, Odirlei Andre Monticielo⁹, Sandra Lúcia Ribeiro¹⁰, Felipe Omura¹¹, Adriana Marinho¹², Francinne Ribeiro¹³, Laurindo Rocha Jr¹⁴, Ana Silvia Martins¹⁵, Michel Yazbek¹⁶, Mariana Souza¹⁷, Nathália Sacilotto¹⁸, Samuel Shinjo¹⁹, Lilian Valadares²⁰, Ana Silva²¹, Danielle Christine de Brito²², Viviane de Souza²³, Carolina Costa²⁴, Samia Studart²⁵, Antônio Ximenes²⁶ and Ricardo Xavier²⁷, ¹Hospital das Clnicas - Universidade Federal de Pernambuco - UFPE, Recife, Brazil, ²Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁴UNIFESP, São Paulo, Brazil, ⁵Universidade Federal de São Paulo, São Paulo, Brazil, ⁶FACISB, Ribeirao Preto, Brazil, ⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁸Universidade de Brasília, Brasilia, Brazil, ⁹Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁰Universidade Federal do Amazonas, Amazonas, Brazil, ¹¹Clinica Omura, São Paulo, Brazil, ¹²FUNDHACRE, Rio Branco, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ¹⁵UFU, Uberlandia, MG, Brazil, ¹⁶UNICAMP, Campinas, Brazil, ¹⁷SCBH, Belo Horizonte, Brazil, ¹⁸Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil, ¹⁹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁰HOSPITAL GETULIO VARGAS, Recife, Brazil, ²¹UFG, GOIANIA, Goias, Brazil, ²²UFPB, Joao Pessoa, Brazil, ²³UFJF, JUIZ DE FORA, Brazil, ²⁴UFES, Vitoria, Brazil, ²⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ²⁶CLINICA CIP, Goiania, Brazil, ²⁷Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: The COVID-19 pandemic has brought uncertainties to the rheumatological practice, and despite the large number of publications to date, many questions remain unanswered. One…
Abstract Number: 1551 • ACR Convergence 2021
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
Tal Gazitt¹, Joy Feld², Amir Haddad³, Muna Elias⁴, Nizar Hijazi⁴, Nili Stein⁴, Victoria Furer⁵, Tali Eviatar⁶, Hagit Peleg⁷, Ori Elkayam⁸ and Devy Zisman⁴, ¹Carmel Hospital, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Givataim, Israel, ⁷Hadassah Medical Center, Jerusalem, Israel, ⁸Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The rapid spread of the COVID-19 pandemic has created the need for mass vaccination of patients with autoimmune rheumatic disease (AIIRD) despite the lack…
Abstract Number: 1592 • ACR Convergence 2021
ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic
Tessa Englund¹, Saira Sheikh², Becki Cleveland¹, Emily McCormick¹, Crystal Schiller³ and Teresa Dickson¹, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality…
Abstract Number: 1611 • ACR Convergence 2021
A Population-Based Evaluation of Telemedicine Use and Satisfaction in SLE Patients During the COVID-19 Pandemic in Atlanta, Georgia
Sarah Simmons¹, Cristina Drenkard², Gaobin Bao², Charmayne Dunlop-Thomas², Kim Schofield² and S Sam Lim³, ¹Duke University, Durham, NC, ²Emory University, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic resulted in the shift from in-person physician appointments to the development and proliferation of the use of telemedicine in an attempt…
Abstract Number: 1914 • ACR Convergence 2021
Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
Jonah Levine¹, Deanna Jannat-Khah¹, Vivian Bykerk², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases (SRD) may have modified their medications at the time of…
Abstract Number: 0009 • ACR Convergence 2021
Humoral Immune Responses to SARS-CoV2 Infections and upon Vaccination Against SARS-CoV2
STEPHANIE FINZEL¹, Nicole Peter², Chiara Brand², Beate Fischer², Bärbel Keller², Sebastian Weigang³, Georg Kochs³, Martin Schwemmle³, Siegbert Rieg⁴, Philipp Mathé⁴, Winfried Kern⁴, Lia van der Hoek⁵, Kathrin de la Rosa⁶, Hans-Martin Jäck⁷, Klaus Warnatz², Reinhard Voll⁸ and Hermann Eibel², ¹University Clinic of Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, ²Department of Rheumatology and Clinical Immunology, Medical Faculty, University of Freiburg and Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg, Germany, ³Institute of Virology, University of Freiburg, Freiburg, Germany, ⁴Department of Infectiology, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁵Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁶Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany, ⁷Department of Medicine 3. Division of Immunology, Friedrich-Alexander-University Erlangen, Erlangen, Germany, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
Background/Purpose: We compared humoral immune responses against SARS-CoV-2 to responses against spike-antigen after vaccination.Methods: 800 health-care workers from University Medical Center Freiburg, Germany, were pursued…
Abstract Number: 0097 • ACR Convergence 2021
Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Anne Regierer⁵, Jutta Richter⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Janus kinase inhibitors (JAK-i) offer a potent mode of action to treat rheumatic diseases. Little is known on the course and outcome of SARS-CoV-2…
Abstract Number: 0115 • ACR Convergence 2021
Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020
Jasvinder Singh¹, John Richards², Elizabeth Chang³, Amy Joseph⁴ and Bernard Ng⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ³Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁴Washington University / St. Louis VA, St Louis, MO, ⁵VA Puget Sound HCS, Seattle, WA
Background/Purpose: To assess the experience, current practices, views and opinions of rheumatology providers at Veterans Affairs (VA) facilities for the care of the patients with…
Abstract Number: 0616 • ACR Convergence 2021
Race and Socioeconomic Status and COVID-19 Outcomes in Patients with Rheumatic Diseases: Findings from a Tertiary Care Center in the Deep South
Adam Taylor, Dongmei Sun, Jeffrey Foster and Maria I. Danila, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The southern United States is home to a large proportion of non-Hispanic Black Americans, a group which has historically been disproportionately affected by healthcare…
Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Philip Robinson¹, Pedro Machado², Nigil Haroon³, Lianne Gensler⁴, John Reveille⁵, Vanessa Taieb⁶, Thomas Vaux⁶, Carmen Fleurinck⁷, Marga Oortgiesen⁸, Natasha de Peyrecave⁷ and Atul Deodhar⁹, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…
Abstract Number: 1087 • ACR Convergence 2021
The Humoral Immunity of mRNA-Based SARS-CoV2 Vaccine in Autoimmune Rheumatic Disease Patients Receiving Immunomodulators
Omar Alsaed, Eman Satti, Bassam Muthanna, Safna Veettil, Hadil Ashour, Einas Alkuwari and Samar Al Emadi, Hamad Medical corporation, Doha, Qatar
Background/Purpose: Since the spread of different SARS-CoV2 vaccines over the world, there was an uncertainty of the efficacy and safety of these vaccines in autoimmune…
Abstract Number: 1534 • ACR Convergence 2021
Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital
David Martinez-Lopez¹, Diana Prieto-Peña¹, Lara Sánchez-Bilbao¹, Carmen Álvarez-Reguera¹, Alba Herrero-Morant¹, Fabricio Benavides-Villanueva¹, Cristina Corrales-Selaya¹, Martin Trigueros-Vazquez¹, Miguel Ángel gonzalez-Gay², Ricardo Blanco³ and Reinhard Wallmann⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Cantabria Health Service, Santander, Spain
Background/Purpose: Severity factors for COVID-19 have been widely studied in the general population. However, the severity factors and characteristics of COVID-19 in patients with rheumatic…
Abstract Number: 1552 • ACR Convergence 2021
Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection
Inés Perez - Sancristobal¹, Leticia Lopez Pedraza², María Paula Álvarez Hernández¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez⁴, Cristina Martínez - Prada⁴, Luis Rodriguez Rodriguez⁵, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁶, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Spain, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ⁵Hospital Clinico San Carlos, Madrid, Spain, ⁶Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The COVID-19 pandemic continues worldwide and has had a strong impact on public health. From the beginning of the pandemic, efforts were intensified to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].